Security
Curanex Pharmaceuticals Inc Common Stock · CURX
CURXNASDAQCommon stockCurrentCIK 2025942Updated Oct 20, 2026
CURX price & chart
Loading TradingView…
NASDAQ:CURX on TradingView ↗About the company
Curanex is a developmental stage pharmaceutical company dedicated to discovering, developing and commercializing innovative botanical drugs to treat patients suffering from inflammatory diseases. Our mission is to address significant unmet medical needs and improve patients’ lives by harnessing the power of natural substances. We are dedicated to discovering, developing and commercializing botanical medicines for treating patients with immune and inflammatory diseases and to develop therapies that may offer potential benefits to patients with unmet clinical needs in various fields, such as autoimmune diseases, metabolic diseases and viral infections.
In the news
No coverage from other publishers is available.
Recent filings
S-8 filing
Other Events
Items 8.01
Other Events
Items 8.01
Material Modification to Rights of Security Holders · Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Items 3.03, 5.03, 9.01
10-Q filing
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 |
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| AssetsUSD | 14,478,157Source | — | 5,073,932Source | 787,174Source | — | 8,411,292Source | — | 11,580,124Source | 517,935Source |
| Current assets: | |||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 5,800,000Source | — | 2,938,463Source | — | — | 4,000,000Source | — | 5,000,000Source | — |
| Assets, CurrentUSD | 14,417,759Source | — | 4,792,993Source | 711,337Source | — | 8,093,718Source | — | 11,227,508Source | 517,935Source |
| Operating Lease, Right-of-Use AssetUSD | 60,398Source | — | 280,939Source | 75,837Source | — | 317,574Source | — | 352,616Source | — |
| LIABILITIES AND EQUITY | |||||||||
| LiabilitiesUSD | 185,955Source | — | 286,254Source | 481,743Source | — | 332,644Source | — | 361,040Source | 14,575Source |
| Stockholders’ equity: | |||||||||
| Preferred Stock, Value, IssuedUSD | 100Source | — | 100Source | 100Source | — | 100Source | — | 100Source | 100Source |
| Common Stock, Value, IssuedUSD | 2,834Source | — | 2,836Source | 2,400Source | — | 2,836Source | — | 2,834Source | 2,400Source |
| Retained Earnings (Accumulated Deficit)USD | -1,774,437Source | — | -11,288,753Source | -820,378Source | — | -7,997,783Source | — | -4,847,555Source | -622,449Source |
| Stockholders' Equity Attributable to ParentUSD | 14,292,202Source | 624,165Source | 4,787,678Source | 305,431Source | 715,231Source | 8,078,648Source | 365,777Source | 11,219,084Source | 503,360Source |
| Additional Paid in Capital, Common StockUSD | 16,063,705Source | — | 16,073,495Source | 923,309Source | — | 16,073,495Source | — | 16,063,705Source | 923,309Source |
| Liabilities and EquityUSD | 14,478,157Source | — | 5,073,932Source | 787,174Source | — | 8,411,292Source | — | 11,580,124Source | 517,935Source |
| Current liabilities: | |||||||||
| Liabilities, CurrentUSD | 185,955Source | — | 104,306Source | 75,927Source | — | 128,734Source | — | 137,030Source | 14,575Source |
| Operating Lease, Liability, CurrentUSD | 61,150Source | — | 94,411Source | 70,636Source | — | 107,090Source | — | 122,689Source | — |
| Accounts Payable, CurrentUSD | 114,489Source | — | 154Source | 269Source | — | 8,404Source | — | 2,426Source | 5,000Source |
| Operating Lease, Liability, NoncurrentUSD | — | — | 181,948Source | 5,816Source | — | 203,910Source | — | 224,010Source | — |
| Additional Financial Items | |||||||||
| Accrued Liabilities, CurrentUSD | 10,316Source | — | 9,741Source | 575Source | — | 13,240Source | — | 11,915Source | 9,575Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||
| Changes in operating assets and liabilities: | ||||||||||
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | 5,978Source | 121,057Source | -2,574Source | 5,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -954,560Source | -149,948Source | -10,484,452Source | -555,575Source |
| Cash flows from financing activities: | ||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | — | 200,000Source | 15,308,695Source | 630,100Source |
| Additional Financial Items | ||||||||||
| General and Administrative ExpenseUSD | — | — | 273,853Source | 93,295Source | 731,843Source | 57,658Source | 927,197Source | 137,452Source | 1,253,203Source | 290,386Source |
| InterestExpenseNonoperatingUSD | — | — | 4,090Source | — | — | 3,091Source | — | 1,356Source | 8,537Source | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -954,059Source | -91,166Source | -3,290,970Source | -60,346Source | -3,150,228Source | -137,583Source | -4,225,106Source | -361,506Source |
| Operating ExpensesUSD | — | — | 951,327Source | 93,295Source | 3,325,560Source | 57,658Source | 3,183,359Source | 137,452Source | 4,239,076Source | 365,062Source |
| Operating Lease, ExpenseUSD | — | — | 17,404Source | — | 40,494Source | 17,404Source | 39,443Source | 17,404Source | 88,040Source | — |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | — | — | 630,000Source |
| Share-based Payment Arrangement, Noncash Expense | — | — | — | — | — | — | —Source | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income (Loss)USD | — | — | -951,327Source | -93,295Source | -3,325,560Source | -57,658Source | -3,183,359Source | -137,452Source | -4,239,076Source | -365,062Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -954,059Source | -91,166Source | -3,290,970Source | -60,346Source | -3,150,228Source | -137,583Source | -4,225,106Source | -361,506Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.04Source | -0.04Source | -0.12Source | 0Source | -0.11Source | -0.01Source | -0.17Source | -0.03Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.04Source | -0.04Source | -0.12Source | 0Source | -0.11Source | -0.01Source | -0.17Source | -0.03Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 25,599,673Source | 2,400,000Source | 28,364,812Source | 24,000,000Source | 28,344,545Source | 24,000,000Source | 25,497,328Source | 13,259,016Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 25,599,673Source | 2,400,000Source | 28,364,812Source | 24,000,000Source | 28,344,545Source | 24,000,000Source | 25,497,328Source | 13,259,016Source |
| Interest Expense (non-operating)USD | — | — | 4,090Source | — | — | 3,091Source | — | 1,356Source | 8,537Source | — |
| Additional Financial Items | ||||||||||
| General and Administrative ExpenseUSD | — | — | 273,853Source | 93,295Source | 731,843Source | 57,658Source | 927,197Source | 137,452Source | 1,253,203Source | 290,386Source |
| Operating ExpensesUSD | — | — | 951,327Source | 93,295Source | 3,325,560Source | 57,658Source | 3,183,359Source | 137,452Source | 4,239,076Source | 365,062Source |
| Operating Lease, ExpenseUSD | — | — | 17,404Source | — | 40,494Source | 17,404Source | 39,443Source | 17,404Source | 88,040Source | — |
| Other General ExpenseUSD | — | — | — | — | — | — | — | — | — | 74,676Source |
| Research and Development ExpenseUSD | — | — | 677,474Source | — | 2,593,717Source | — | 2,256,162Source | — | 2,985,873Source | — |
Offerings
Registration 333-282686
- Offering price
- market-price
- Ticker
- CURX
Filing attachments
ex107.htm · S-8 · 2026-10-19
Calculation of Filing Fee Tables S-8 Curanex Pharmaceuticals Inc ──────────────────────────────────── Table 1: Newly Registered Securities ──────────────────────────────────────── Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee ──────────────────────────────────────…
Read attachment ↗ex107.htm · S-8 · 2026-07-21
Calculation of Filing Fee Tables S-8 Curanex Pharmaceuticals Inc ──────────────────────────────────── Table 1: Newly Registered Securities ──────────────────────────────────────── Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee ─────────────────────────────────────…
Read attachment ↗ex99-1.htm · S-8 · 2026-07-21
Exhibit 99.1 CURANEX PHARMACEUTICALS INC 2026 EQUITY INCENTIVE PLAN Approved by the Board: May 31, 2026 Approved by the Stockholders: June 11, 2026 1. Purposes of the Plan. The purposes of this Plan are to attract and retain the best available personnel; to provide additional incentives to Employees, Directors and Consultants to contribute to the successful performance of the Company and any Related Entity; to promote the growth of the market value of the Company’s Common Stock; to align th…
Read attachment ↗ex99-1.htm · 8-K · 2026-05-14
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Curanex Reports First Quarter 2026 Business Progress as Phyto-N Advances Toward Planned FDA Submission Completed GMP manufacturing and toxicology milestones supporting planned Q4 2026 IND submission for ulcerative colitis Expanded pipeline strategy to include cancer cachexia, a serious cancer-associated wasting condition with no FDA-approved therapies specifically indicated for the condition Jericho, New York, May 14, 2026 (GLOBE NEWSWIRE) - Cur…
Read attachment ↗ex99-1.htm · 8-K · 2026-04-02
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Curanex Expands Its Drug Development Pipeline to Include Cancer Cachexia, Representing a Multi-Billion-Dollar Market Opportunity and Important Step In The Company’s Evolution Into a Broader Therapeutics Development Company Company expands strategic focus into one of oncology’s most urgent supportive-care challenges Jericho, New York, April 2, 2026 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals, Inc. (Nasdaq: CURX) (“Curanex” or the “Company”), a deve…
Read attachment ↗ex4-4.htm · 10-K · 2026-03-30
Exhibit 4.4 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Curanex Pharmaceuticals Inc (“Curanex” the “Company,” “we” or “our”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934 - common stock, par value $0.0001 per share (the “Common Stock”). The following is a summary of the material terms of the Common Stock of the Company. It does not purport to be complete and is subject to…
Read attachment ↗